Peptide therapy TikTok claims: separating hype from human data

What did @harms.peps actually say?

The creator argued that injectable peptides offer "higher and better absorption" because they enter subcutaneous fat directly, while nasal sprays trade bioavailability for convenience. They also made the reasonable point that "not all peptides work nasally" because molecular size affects transmucosal absorption. The disclaimer at the end frames everything as research and educational content.

That summary is fair. The video is not sensationalist. It does not promise cures, does not prescribe doses, and it acknowledges variability between individuals and compounds. For a short-form social video on a genuinely complicated pharmacokinetic topic, the core message is more accurate than most of what circulates in peptide communities online.

Does the science back this up?

Mostly, yes. The bioavailability hierarchy they describe is real, but the picture is more nuanced than the video lets on. Subcutaneous injection of peptides like BPC-157 bypasses first-pass metabolism and delivers predictable systemic concentrations. Nasal delivery is more complicated than "less bioavailable" as a blanket statement.

Nasal mucosa offers a direct route to the central nervous system via olfactory and trigeminal pathways, which is why peptides like Semax and Selank were specifically engineered for intranasal use by the Russian Institute of Molecular Genetics. For those compounds, nasal delivery is not a compromise. It is the intended and studied route. Research by Illum (2000, Journal of Controlled Release) established that molecular weight is a primary determinant of nasal absorption, with peptides under roughly 1,000 daltons crossing nasal epithelium more efficiently. BPC-157 sits around 1,419 daltons, which is why nasal administration of that peptide specifically is far less studied and supported than subcutaneous injection. The creator is right that size matters, but calling all nasal peptide use a convenience trade-off misses the Semax and Selank exception.

What did they get wrong (or right)?

They got the molecular size point right, and that is the most scientifically grounded claim in the video. Credit where it is due. The claim that "absorption can differ depending on the person" is also accurate. Nasal mucosal blood flow, mucus thickness, and enzymatic activity vary considerably between individuals (Patel et al., 2015, Drug Delivery).

Where the video is incomplete is in treating nasal delivery as universally inferior. For neurologically active peptides designed for intranasal use, the nasal route is not a bioavailability compromise. It is a targeted delivery mechanism. Semax, for instance, has peer-reviewed pharmacokinetic data from Russian clinical literature supporting intranasal administration specifically because CNS penetration via olfactory transport is the goal, not systemic circulation. The creator's framing of "convenience versus accuracy" does not apply to that class of peptides. That omission is not a dangerous error, but it is worth correcting because it could lead someone to assume injectable Semax is categorically superior when the existing evidence does not support that conclusion.

What should you actually know?

Route of administration is compound-specific, not a universal ranking. Asking whether nasal or injectable is better is like asking whether oral or topical is better. It depends entirely on what you are taking and why.

For large peptides like CJC-1295 or BPC-157, subcutaneous injection produces more consistent and studied pharmacokinetics. Intranasal administration of those compounds lacks adequate human bioavailability data. For peptides engineered for CNS activity, like Semax and Selank, intranasal delivery may actually be more appropriate than systemic injection for reaching target tissues. The broader issue is that most of the peptides discussed in online wellness content have limited or no human clinical trial data regardless of route. The existing research is largely animal-based or derived from small Russian clinical studies that have not been replicated in large Western trials. Anyone using these compounds, by any route, is operating in a low-evidence space. The creator acknowledges the educational framing, which is appropriate given that reality.